Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

ICECaP 2023

Updates from ICECaP: Adjuvant Localized Prostate Cancer

Chris Sweeney

Director, South Australian Immunogenomics Cancer Institute

Professor of Medicine, University of Adelaide

View Presentation

Progress in credentialing the decreased detrimental effects associated with decreased PSA relapse as an endpoint in adjuvant prostate cancer trials

Richard de Abreu Lourenco & Chris Sweeney

View Presentation

STOPCAP M1: IPD meta-analyses to help determine which men with mHSPC should receive second-generation anti-androgens, docetaxel or their combination

Jayne Tierney

Evidence Synthesis
University College London

View Presentation

Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in Subgroups of men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Susan Halabi

Biostatistics and Bioinformatics,
Duke University

View Presentation

Discovery and qualification of multi-modality biomarkers for men starting long-term ADT in the STAMPEDE trial

Emily Grist

UCL Cancer Institute and Royal Marsden NHS Foundation Trust

View Presentation

Update on CHAARTED and ENZAMET Translational Science

Anis Hamid

Medical Oncology,
University of Melbourne

View Presentation

ICECaP 2022

Multi-national collaborative strategies for validating a biomarker for HSPC

Gerhardt Attard

Medical Oncology, Uni College London

View Presentation

Next Steps for ICECaP2: Planned analyses of different treatment effects in subgroups and exploring earlier intermediate clinical endpoints

Chris Sweeney

ICECaP Principal Investigator, medical Oncology, Dana-Farber Cancer Institute

View Presentation

Using surrogate outcomes to demonstrate value in adjuvant prostate cancer: An update

Richard De Abreu Lourenco

Health Economics, University of Technology Sydney

View Presentation

HARMONIZATION Progress of writing a guidance document for conduct of adjuvant prostate cancer trials

Anis Hamid

Medical Oncology, University of Melbourne

View Presentation

STOPCaP: Treatment effect - Progress on IPD data collection and network meta-analyses for treatment effects

Jayne Tierney

Evidence Synthesis, University College London

View Presentation

Identification of Surrogate Endpoints and Developing and Validating Prognostic Models in Metastatic Hormone Sensitive Prostate Cancer

Susan Halabi

Biostatistics and Bioinformatics, Duke University

View Presentation

ICECaP 2021

Opening Remarks

Paul Villanti, Executive Director Programs, Movember

Chris Sweeney, ICECaP Principal Investigator, Medical Oncology, Dana-Farber Cancer Institute

ICECaP Updates

Chris Sweeney

ICECaP Principal Investigator,
Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Update on data collection for ICECaP2

Praful Ravi

Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Example of assessing new PSA based endpoints

Wanling Xie

Biostatistics,
Dana-Farber Cancer Institute.

View Presentation

Progress on creating a health economics model in adjuvant prostate cancer setting

Richard De Abreu Lourenco

Health Ecocomics,
University of Technology Sydney

View Presentation

Discuss goal to credential QALY gained from preventing a PSA relapse as an endpoint

Chris Sweeney

ICECaP Principal Investigator,
Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Progress of writing a guidance document for conduct of adjuvant trials

Anis Hamid

Medical Oncology, University of Melbourne

View Presentation

Progress on IPD data collection and network meta-analyses for treatment effects

Jayne Tierney

Evidence Synthesis
University College London

View Presentation

Progress on prognostic models and surrogacy

Susan Halabi

Biostatistics and Bioinformatics, Duke University

View Presentation

Proposal of simple prognostic model

Chris Sweeney

Medical Oncology
Dana-Farber Cancer Institute

View Presentation

ICECaP Biology 2021

Gerhardt Attard
Medical Oncology, Uni College London

Progress: prelim data, sample collection, and plans:

M1HSPC: STAMPEDE-ADT, doc, abi; CHAARTED; ENZAMET, PEACE-1
Adjuvant: STAMPEDE-ADT, doc, abi; NRG; ENZARAD